177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

被引：19
|
作者：
Assadi, Majid [1 ]
Pirayesh, Elahe [2 ]
Rekabpour, Seyed Javad [3 ]
Zohrabi, Farshad [4 ]
Jafari, Esmail [1 ]
Nabipour, Iraj [5 ]
Esmaili, Abdolhamid [6 ]
Amini, Abdullatif [7 ]
Ahmadzadehfar, Hojjat [8 ]
机构：
[1] Bushehr Univ Med Sci, Bushehr Med Univ Hosp, Persian Gulf Nucl Med Res Ctr, Dept Mol Imaging & Radionuclide Therapy,Fac Med, Bushehr, Iran
[2] Shahid Beheshti Univ Med Sci, Shohada & Tajrish Med Ctr, Dept Nucl Med, Tehran, Iran
[3] Bushehr Med Univ Hosp, Dept Oncol, Bushehr, Iran
[4] Bushehr Med Univ Hosp, Dept Urol, Bushehr, Iran
[5] Bushehr Med Univ Hosp, Dept Internal Med, Div Endocrinol, Bushehr, Iran
[6] Bushehr Med Univ Hosp, Dept Pathol, Bushehr, Iran
[7] Bushehr Univ Med Sci, Dept Cardiol, Bushehr Heart Med Ctr, Bushehr, Iran
[8] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 12期
关键词：
prostate cancer; neuroendocrine differentiation; Lu-177-PSMA; Lu-177-DOTATATE; GA-68-PSMA; MEDICINE;
D O I：
10.1097/RLU.0000000000002824
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
We presented a promising result of radionuclide therapy using Lu-177-PSMA and Lu-177-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.
引用
收藏
页码：978 / 980
页数：3
相关论文
共 50 条
  • [1] Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy
    Liu, Chen
    Liu, Teli
    Zhang, Jingjing
    Baum, Richard P.
    Yang, Zhi
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (11) : 876 - 878
  • [2] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [3] Prostate Cancer With Neuroendocrine Differentiation Recurring After Treatment With 177Lu-PSMA A Chance for 177Lu-DOTATATE Therapy?
    Nesari Javan, Farnaz
    Aryana, Kamran
    Askari, Emran
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : E480 - E482
  • [4] Dual 177Lu-Prostate-Specific Membrane Antigen and 177Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation
    Beyhan, Ediz
    Fenercioglu, Ozge Erol
    Sahin, Rahime
    Cermik, Tevfik Fikret
    Ergul, Nurhan
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (05) : 447 - 448
  • [5] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [6] High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Groener, D.
    Davis, K. H.
    Wichert, J.
    Stefanova, M.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S647 - S648
  • [7] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [8] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [9] Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer
    Hindie, Elif
    LANCET ONCOLOGY, 2021, 22 (10): : E425 - E425
  • [10] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    PHARMACEUTICS, 2022, 14 (10)
12345